anonymous
Guest
anonymous
Guest
It's been confirmed that MNK has ben trying to rid itself of Acthar for the past several months, even offering a business plan to another large pharmaceutical company with 0% interest loan for approximately 5 or more years. Brokers an insiders state that sales for Q1 (MNK) are way of pace and shareholders are growing more and more concerned over the fact that MT has just 3 very short quarters to ensure that the goals are met.
*The market is waiting to bounce on the news of another price increase-thus serving as a leading indicator that less and less vials are being sold quarterly. News Flash!!!!
The number one rule of 'holes' is to stop digging!!!! Admit that you have a problem and the company is working hard to overcome recent trends. Lastly there have been more than 15-20 departures within ARD, and these departures will cost the company millions of dollars in sales.
But you guys have a plan, take another course in lying to wall street-time is running out
*The market is waiting to bounce on the news of another price increase-thus serving as a leading indicator that less and less vials are being sold quarterly. News Flash!!!!
The number one rule of 'holes' is to stop digging!!!! Admit that you have a problem and the company is working hard to overcome recent trends. Lastly there have been more than 15-20 departures within ARD, and these departures will cost the company millions of dollars in sales.
But you guys have a plan, take another course in lying to wall street-time is running out